X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3320) 3320
life sciences & biomedicine (3130) 3130
humans (2814) 2814
animals (1971) 1971
mice (1109) 1109
janus kinase 2 - antagonists & inhibitors (1029) 1029
signal transduction (994) 994
male (867) 867
janus kinase 2 - metabolism (824) 824
signal transduction - drug effects (818) 818
janus kinase 2 (804) 804
female (798) 798
phosphorylation (746) 746
oncology (741) 741
janus kinases - antagonists & inhibitors (664) 664
protein kinase inhibitors - pharmacology (622) 622
cell biology (595) 595
hematology (576) 576
stat3 transcription factor - metabolism (574) 574
janus kinase 2 - genetics (551) 551
cell line, tumor (543) 543
janus kinase (520) 520
biochemistry & molecular biology (503) 503
kinases (483) 483
cells, cultured (463) 463
janus kinases - metabolism (450) 450
protein kinase inhibitors - therapeutic use (445) 445
cytokines (437) 437
immunology (435) 435
protein-tyrosine kinases - metabolism (434) 434
abridged index medicus (432) 432
pharmacology & pharmacy (425) 425
rats (414) 414
apoptosis (403) 403
cell line (401) 401
mutation (389) 389
enzyme inhibitors - pharmacology (385) 385
protein-tyrosine kinases - antagonists & inhibitors (374) 374
proteins (365) 365
research (357) 357
apoptosis - drug effects (348) 348
middle aged (347) 347
phosphorylation - drug effects (346) 346
gene expression (336) 336
janus kinase 1 - antagonists & inhibitors (328) 328
tyrphostins - pharmacology (313) 313
cell proliferation - drug effects (295) 295
analysis (287) 287
stat3 transcription factor - antagonists & inhibitors (286) 286
adult (279) 279
inflammation (279) 279
janus kinase 3 - antagonists & inhibitors (267) 267
proto-oncogene proteins (262) 262
pyrazoles - therapeutic use (260) 260
signal transduction - physiology (259) 259
aged (253) 253
treatment outcome (253) 253
pyrimidines - pharmacology (249) 249
cancer (245) 245
antineoplastic agents - pharmacology (243) 243
primary myelofibrosis - drug therapy (243) 243
care and treatment (242) 242
jak2 (242) 242
stat transcription factors - metabolism (242) 242
dna-binding proteins - metabolism (236) 236
research article (236) 236
health aspects (235) 235
genetic aspects (232) 232
hemic and lymphatic diseases (231) 231
trans-activators - metabolism (228) 228
dose-response relationship, drug (227) 227
mice, inbred c57bl (227) 227
stat3 protein (222) 222
janus kinase 1 - metabolism (209) 209
pyrimidines - therapeutic use (206) 206
rheumatoid arthritis (206) 206
physiological aspects (203) 203
myelofibrosis (201) 201
tumors (199) 199
disease models, animal (195) 195
medicine, research & experimental (195) 195
research & experimental medicine (195) 195
blotting, western (194) 194
rodents (193) 193
pyrazoles - pharmacology (192) 192
janus kinase 1 (191) 191
science & technology - other topics (189) 189
multidisciplinary sciences (187) 187
stat3 (186) 186
hormones, hormone substitutes, and hormone antagonists (185) 185
stat3 transcription factor - genetics (185) 185
transcription (183) 183
stat5 transcription factor - metabolism (181) 181
medicine (177) 177
leukemia (173) 173
rats, sprague-dawley (173) 173
signaling (170) 170
tumor cells, cultured (169) 169
cell proliferation (163) 163
jak (163) 163
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3944) 3944
Japanese (31) 31
Chinese (16) 16
German (11) 11
French (9) 9
Russian (6) 6
Spanish (6) 6
Danish (3) 3
Portuguese (2) 2
Croatian (1) 1
Czech (1) 1
Finnish (1) 1
Italian (1) 1
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 10/2012, Volume 120, Issue 17, pp. 3510 - 3518
CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been identified in Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Immunoglobulins - genetics | Molecular Targeted Therapy | Immunoglobulins - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Janus Kinase 1 - metabolism | STAT5 Transcription Factor - genetics | STAT5 Transcription Factor - metabolism | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | TOR Serine-Threonine Kinases - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Receptors, Cytokine - metabolism | Drug Evaluation, Preclinical | Child | Philadelphia Chromosome | Receptors, Cytokine - genetics | Janus Kinase 2 - antagonists & inhibitors | Disease Models, Animal | Pyrazoles - pharmacology | Acute Disease | Janus Kinase 2 - genetics | Survival Rate | Signal Transduction - genetics | Janus Kinase 1 - antagonists & inhibitors | Sirolimus - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 05/2005, Volume 25, Issue 5, pp. 950 - 956
OBJECTIVE—Reactive oxygen species (ROS) integrate cellular signaling pathways involved in aortic smooth muscle cell (SMC) proliferation and migration... 
SMC | SOD | Thrombin | Cell signaling | ROS | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | MAP Kinase Signaling System - physiology | Superoxide Dismutase - genetics | Reactive Oxygen Species - metabolism | Protein-Tyrosine Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - metabolism | Janus Kinase 2 | Mice, Mutant Strains | p38 Mitogen-Activated Protein Kinases - metabolism | Aorta - enzymology | STAT3 Transcription Factor - metabolism | Superoxide Dismutase - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Atherosclerosis - pathology | Mice, Inbred C57BL | Cells, Cultured | Enzyme Inhibitors - pharmacology | Atherosclerosis - metabolism | Cell Division - drug effects | Aorta - pathology | Cell Compartmentation - physiology | Cell Division - physiology | Gene Expression Regulation, Enzymologic | Muscle, Smooth, Vascular - pathology | Animals | MAP Kinase Signaling System - drug effects | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Mice | Superoxide Dismutase-1 | Muscle, Smooth, Vascular - enzymology | Hypertrophy | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Annual review of biochemistry, ISSN 0066-4154, 2006, Volume 75, Issue 1, pp. 93 - 109
.... In spite of the conservation among protein tyrosine kinases (PTKs), one can develop small molecules that block the activity of a narrow spectrum of PTKs and that exhibit much less toxicity than the currently used chemotherapeutic agents... 
Signal transduction | Tyrphostin | Tyrosine phosphorylation | Cancer therapy | Erlotinib Hydrochloride | Protein-Tyrosine Kinases - metabolism | Humans | Graft Occlusion, Vascular - prevention & control | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Piperazines - metabolism | Antineoplastic Agents - therapeutic use | Piperazines - chemistry | Pyrimidines - chemistry | Pyrimidines - metabolism | Antineoplastic Agents - metabolism | Janus Kinase 3 - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Fusion Proteins, bcr-abl | Quinazolines - metabolism | Adenosine Triphosphate - metabolism | Janus Kinase 2 - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Molecular Structure | Janus Kinase 3 - metabolism | Tyrphostins - chemistry | Quinazolines - chemistry | Janus Kinase 2 - antagonists & inhibitors | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Piperazines - therapeutic use | Antineoplastic Agents - chemistry | Imatinib Mesylate | Tyrphostins - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptors, Platelet-Derived Growth Factor - metabolism | Tyrphostins - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Signal Transduction - physiology | Benzamides | Adenosine Triphosphate - chemistry | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 08/2011, Volume 55, Issue 2, pp. 289 - 298
Background & Aims The combination of pegylated interferon (IFN) α and ribavirin (RBV) is the standard therapy for patients with chronic HCV infection. However,... 
Gastroenterology and Hepatology | IL28B | STAT | HCV | JAK | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | RNA, Small Interfering - genetics | Humans | STAT Transcription Factors - metabolism | TYK2 Kinase - metabolism | DNA Primers - genetics | Janus Kinases - metabolism | Interleukins - genetics | Janus Kinase 1 - metabolism | STAT1 Transcription Factor - metabolism | Base Sequence | Hepacivirus - physiology | TYK2 Kinase - antagonists & inhibitors | Interleukins - pharmacology | Phosphorylation - drug effects | Hepacivirus - drug effects | Cell Line | Virus Replication - drug effects | Antiviral Agents - pharmacology | Recombinant Proteins - pharmacology | Interferon-Stimulated Gene Factor 3, gamma Subunit - genetics | Janus Kinase 1 - antagonists & inhibitors | STAT1 Transcription Factor - genetics | Interferon-Stimulated Gene Factor 3, gamma Subunit - metabolism | STAT1 Transcription Factor - antagonists & inhibitors | Receptors, Interferon - metabolism | Janus Kinases - antagonists & inhibitors | STAT2 Transcription Factor - antagonists & inhibitors | Signal Transduction - drug effects | STAT2 Transcription Factor - genetics | Polymorphism, Single Nucleotide | STAT Transcription Factors - antagonists & inhibitors | STAT2 Transcription Factor - metabolism | Virus Replication - physiology | Interferon-Stimulated Gene Factor 3, gamma Subunit - antagonists & inhibitors | Virus diseases | Genetic research | Precipitation (Meteorology) | Biological response modifiers | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
International journal of oncology, ISSN 1019-6439, 03/2013, Volume 42, Issue 3, pp. 1113 - 1119
Journal Article
Neoplasia, ISSN 1476-5586, 2015, Volume 17, Issue 3, pp. 256 - 264
Journal Article
Autoimmunity (Chur, Switzerland), ISSN 1607-842X, 01/2014, Volume 47, Issue 2, pp. 77 - 94
Journal Article
Leukemia, ISSN 1476-5551, 05/2007, Volume 21, Issue 8, pp. 1658 - 1668
...) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC(50) = 169 nM... 
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Apoptosis - drug effects | Humans | STAT Transcription Factors - metabolism | Polycythemia Vera - genetics | Myeloproliferative Disorders - genetics | Janus Kinase 3 - antagonists & inhibitors | Polycythemia Vera - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Janus Kinase 2 - metabolism | Myeloproliferative Disorders - metabolism | Colony-Forming Units Assay | Phosphorylation - drug effects | Janus Kinase 3 - metabolism | Janus Kinase 2 - antagonists & inhibitors | Primary Myelofibrosis - metabolism | Primary Myelofibrosis - drug therapy | Thrombopoietin - metabolism | Enzyme Inhibitors - pharmacology | Janus Kinase 2 - genetics | Myeloproliferative Disorders - drug therapy | Pyrimidines - pharmacology | Mice, SCID | Mutation - genetics | Sulfonamides - pharmacology | Receptors, Thrombopoietin - metabolism | Receptors, Thrombopoietin - antagonists & inhibitors | fms-Like Tyrosine Kinase 3 - metabolism | Receptors, Thrombopoietin - genetics | Primary Myelofibrosis - genetics | Animals | Janus Kinase 3 - genetics | Stem Cells - drug effects | Polycythemia Vera - drug therapy | Cell Proliferation - drug effects | Mice | Cell Cycle - drug effects | Antibody diversity | Chemical inhibitors | Genetic aspects | Research | Health aspects | Myeloproliferative disorders | Index Medicus
Journal Article